Skip to content

Study · Animal study (in vivo) · mouse · 2018

11 results

Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury.

Cai J, Jiang Y, Zhang M, Zhao H, Li H, Li K, Zhang X, Qiao T

Journal of physiology and biochemistry27 Mar 2018Cited by 35 (Europe PMC)

PMID29589186 (opens in a new tab)DOI10.1007/s13105-018-0617-1 (opens in a new tab)PepBankPUB-29589186
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with hind limb ischemia-reperfusion injury, SS‑31 treatment prevented the IR-induced histological deterioration compared with vehicle.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 prevented tissue damage compared with vehicle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseHistological deterioration after IR
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Comparator
    Vehicle
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histopathologically, SS-31 treatment prevented the IR-induced histological deterioration compared with the corresponding vehicle control.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, SS‑31 reduced the malondialdehyde level.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 lowered malondialdehyde, a marker of oxidative damage.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMalondialdehyde level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 treatment diminished oxidative stress revealed by the reduced malondialdehyde level and increased activities and protein levels of Sod and catalase.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, SS‑31 increased the activity and protein levels of Sod.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 raised the activity and level of the antioxidant enzyme Sod.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSod activity and protein level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 treatment diminished oxidative stress revealed by the reduced malondialdehyde level and increased activities and protein levels of Sod and catalase.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, SS‑31 increased the activity and protein levels of catalase.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 raised the activity and level of the antioxidant enzyme catalase.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCatalase activity and protein level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 treatment diminished oxidative stress revealed by the reduced malondialdehyde level and increased activities and protein levels of Sod and catalase.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, cellular ATP contents increased after SS‑31 treatment.

    In plain wordsIn mice with hind limb injury after blocked blood flow, cell ATP (energy) content rose after SS‑31 treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCellular ATP content
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cellular ATP contents and mitochondrial membrane potential increased and the level of cytosolic cytC was decreased after SS-31 treatment in this IR model, demonstrating that mitochondria were protected.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, mitochondrial membrane potential increased after SS‑31 treatment.

    In plain wordsIn mice with hind limb injury after blocked blood flow, mitochondrial membrane potential rose after SS‑31 treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cellular ATP contents and mitochondrial membrane potential increased and the level of cytosolic cytC was decreased after SS-31 treatment in this IR model, demonstrating that mitochondria were protected.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, the level of cytosolic cytochrome c decreased after SS‑31 treatment.

    In plain wordsIn mice with hind limb injury after blocked blood flow, cytosolic cytochrome c fell after SS‑31 treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCytosolic cytochrome c level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cellular ATP contents and mitochondrial membrane potential increased and the level of cytosolic cytC was decreased after SS-31 treatment in this IR model, demonstrating that mitochondria were protected.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, SS‑31 treatment prevented the IR-induced increase of Tnf-α.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 prevented the rise in the inflammation signal Tnf-α.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTnf-α level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The IR-induced increase of levels of inflammatory factors, such as Tnf-α and Il-1β, was prevented by SS-31 treatment.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, SS‑31 treatment prevented the IR-induced increase of Il-1β.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 prevented the rise in the inflammation signal Il-1β.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseIl-1β level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The IR-induced increase of levels of inflammatory factors, such as Tnf-α and Il-1β, was prevented by SS-31 treatment.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with hind limb ischemia-reperfusion injury, cleaved caspase 3 was kept at a very low level after SS‑31 treatment.

    In plain wordsIn mice with hind limb injury after blocked blood flow, a cell-death marker stayed very low after SS‑31 treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCleaved caspase 3 level
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In agreement with the reduced cytosolic cytC, cleaved-caspase 3 was kept at a very low level after SS-31 treatment.
    1 context sentence
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice with hind limb ischemia-reperfusion injury, SS‑31 given before or after ischemia had similar protective effects, but treatment before ischemia was mildly more effective overall.

    In plain wordsIn mice with hind limb injury after blocked blood flow, SS‑31 protected whether given before or after, with a slight edge when given before.

    Peptide
    Elamipretide (SS-31)
    Outcome
    MixedTiming of SS-31 treatment (before versus after ischemia)
    Study

    mousen: not reported in source

    Hind limb ischemia-reperfusion injury model
    Comparator
    SS-31 after ischemia
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that SS-31 treatment either before or after ischemia exhibited similar protective effects.
    2 context sentences
    Summary · context
    Overall, the effect of SS-31 treatment before ischemia is mildly more effective than that after ischemia.
    Summary · context
    In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.